Alpha Teknova (NASDAQ:TKNO) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Alpha Teknova (NASDAQ:TKNO - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04, Zacks reports. The business had revenue of $9.29 million during the quarter, compared to the consensus estimate of $7.80 million. Alpha Teknova had a negative return on equity of 37.35% and a negative net margin of 97.85%. During the same period in the prior year, the firm posted ($0.31) EPS. Alpha Teknova updated its FY 2024 guidance to EPS.

Alpha Teknova Price Performance

Shares of NASDAQ TKNO traded down $0.07 during mid-day trading on Wednesday, reaching $1.88. 5,199 shares of the company traded hands, compared to its average volume of 13,546. Alpha Teknova has a fifty-two week low of $1.66 and a fifty-two week high of $4.27. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.14 and a quick ratio of 3.84. The firm has a market cap of $76.74 million, a PE ratio of -1.79 and a beta of 0.39. The stock has a fifty day simple moving average of $2.32 and a 200-day simple moving average of $2.73.

Analyst Upgrades and Downgrades

TKNO has been the subject of several recent analyst reports. BTIG Research downgraded Alpha Teknova from a "buy" rating to a "neutral" rating in a research note on Tuesday, March 12th. Stephens restated an "overweight" rating and set a $15.00 target price on shares of Alpha Teknova in a research note on Tuesday.

About Alpha Teknova

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.